Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

144 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The Multifaceted Role of TGF-β in Gastrointestinal Tumors.
Sabbadini F, Bertolini M, De Matteis S, Mangiameli D, Contarelli S, Pietrobono S, Melisi D. Sabbadini F, et al. Among authors: melisi d. Cancers (Basel). 2021 Aug 5;13(16):3960. doi: 10.3390/cancers13163960. Cancers (Basel). 2021. PMID: 34439114 Free PMC article. Review.
EMT and Treatment Resistance in Pancreatic Cancer.
Gaianigo N, Melisi D, Carbone C. Gaianigo N, et al. Among authors: melisi d. Cancers (Basel). 2017 Sep 12;9(9):122. doi: 10.3390/cancers9090122. Cancers (Basel). 2017. PMID: 28895920 Free PMC article. Review.
Plasma IL8 Is a Biomarker for TAK1 Activation and Predicts Resistance to Nanoliposomal Irinotecan in Patients with Gemcitabine-Refractory Pancreatic Cancer.
Merz V, Zecchetto C, Santoro R, Simionato F, Sabbadini F, Mangiameli D, Piro G, Cavaliere A, Deiana M, Valenti MT, Bazan D, Fedele V, Lonardi S, Melisi D. Merz V, et al. Among authors: melisi d. Clin Cancer Res. 2020 Sep 1;26(17):4661-4669. doi: 10.1158/1078-0432.CCR-20-0395. Epub 2020 Jun 12. Clin Cancer Res. 2020. PMID: 32532788 Clinical Trial.
A phase II trial of the FGFR inhibitor pemigatinib in patients with metastatic esophageal-gastric junction/gastric cancer trastuzumab resistant: the FiGhTeR trial.
Merz V, Zecchetto C, Simionato F, Cavaliere A, Casalino S, Pavarana M, Giacopuzzi S, Bencivenga M, Tomezzoli A, Santoro R, Fedele V, Contarelli S, Rossi I, Giacomazzi S, Pasquato M, Piazzola C, Milleri S, de Manzoni G, Melisi D. Merz V, et al. Among authors: melisi d. Ther Adv Med Oncol. 2020 Jul 7;12:1758835920937889. doi: 10.1177/1758835920937889. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 32684989 Free PMC article.
Targeting KRAS: The Elephant in the Room of Epithelial Cancers.
Merz V, Gaule M, Zecchetto C, Cavaliere A, Casalino S, Pesoni C, Contarelli S, Sabbadini F, Bertolini M, Mangiameli D, Milella M, Fedele V, Melisi D. Merz V, et al. Among authors: melisi d. Front Oncol. 2021 Mar 11;11:638360. doi: 10.3389/fonc.2021.638360. eCollection 2021. Front Oncol. 2021. PMID: 33777798 Free PMC article. Review.
Exceptional Clinical Response to Alectinib in Pancreatic Acinar Cell Carcinoma With a Novel ALK-KANK4 Gene Fusion.
Gaule M, Pesoni C, Quinzii A, Zecchetto C, Casalino S, Merz V, Contarelli S, Pietrobono S, Vissio E, Molinaro L, Manzin E, Volpatto R, Vellani G, Melisi D. Gaule M, et al. Among authors: melisi d. JCO Precis Oncol. 2022 Jan;6:e2100400. doi: 10.1200/PO.21.00400. JCO Precis Oncol. 2022. PMID: 35005993 Free PMC article. No abstract available.
144 results